Iambic hands its cancer-pill gamble to Nasdaq after $461.8M of private money

The blanks are the pricing fight

On Monday, 21 September 2026, Iambic Therapeutics↗ filed its S-1↗ to list on Nasdaq as IAM, with J.P. Morgan, Jefferies, BofA Securities and Citigroup running the book ¹². The share count and the price range are blank, and those blanks are where the two camps meet ¹. Incorporated in 2019 as Entos, the San Diego company sells what it calls molecular superintelligence: AI models that design molecules, robotic labs that synthesize and test hundreds of compounds per program each week ².

What the fresh cash buys

Renaissance Capital↗ frames the raise at up to $100 million ³. Net proceeds plus existing cash go to three wholly owned cancer programs: IAM1363, an oral, brain-penetrant HER2 inhibitor in a Phase 1/1b trial with a registrational study possible as early as 2027, and IAM217 and IAM-C1, two preclinical candidates with US IND filings expected this quarter ².

The ledger riding along

In 2025 Iambic booked $9.4 million of revenue against a $77.3 million net loss, after $1.2 million and $47.9 million in 2024 ¹². Trailing revenue reached $18 million through 30 June 2026 ³. Every dollar so far is partnership money, not drug sales, and the S-1 concedes the platform has not yet led to an approved drug product ².

Who gets the public mark

Private investors put in about $461.8 million through 18 September 2026; the holders above 5 percent are Catalio, Nexus Ventures, Q Healthcare Holding, Nvidia and Coatue ². Employees hold options on 17.2 million shares at a $1.31 weighted-average strike, and the filing states that prior investors bought at prices lower than the coming public price ². One stated purpose of the offering is to "create a public market" and ease later sales by stockholders and employees ².

The pharma hedge, and a window that keeps clearing

The hedge is in the payment terms. AbbVie, which announced its collaboration↗ the same morning, pays an upfront and then success-based milestones and tiered royalties ⁴; Takeda's February 2026 deal carries success-based payments potentially above $1.7 billion, plus royalties ⁵. The partners pay when programs succeed, while IPO buyers hold the equity straight through failure. Jazz, Bayer, Lundbeck and Revolution Medicines sit on the same partner list ².

Why does the 2026 window keep clearing filings whose losses run near eight times revenue? Because biotech is where the returns are: all five of this year's best-performing IPOs above $50 million are biotechs, with a wave of drugmaker acquisitions underwriting demand, in Renaissance strategist Matt Kennedy's count ⁶. The free pass may be narrowing anyway; Electra Therapeutics raised $350 million in an upsized IPO on Friday and closed down 11.7 percent, and Kennedy expects the sector to draw more scrutiny from here ⁷.

Second Nvidia-backed S-1 in three days

Nscale, the month's other Nvidia-backed filer, posted a $1.02 billion first-half loss on $140.6 million of revenue↗ while chasing a reported $30 billion valuation ⁸, a cap table The Inference unpacked on Monday. Nvidia holds more than 5 percent of Iambic and appears in its partner roster alongside AbbVie and Takeda ²; whether that seat moves the eventual price is the one question the coming amendment will not answer. Watch the amendment that fills in the range, then the fourth-quarter INDs. The private money built the platform. The public money buys the trials.